



Learning objectives of the conference:

- 1) To better understand the pharmacology of cannabis and the physiology of the endocannabinoid system;
- 2) To be aware of the possible therapeutic applications of cannabis for pain and other neuropsychiatric disorders;
- 3) To appreciate the risks of cannabis consumption in the adolescent population and its potential impact on public safety.

- 12:00 Registration and Lunch
- 13:00 Welcome
- 13:05 **Cannabis legalization: social implications** *Benedikt Fischer, PhD (CAMH, University of Toronto)*
- 14:00 Traditional marijuana, high potency cannabis, and synthetic cannabinoids: increasing risk for psychosis Robin Murray, MD, FRS (King's College London, UK)
- 15:00 Coffee break
- 15:15 **Effects on the developing brain: positive and negative?** *Matthew Hill, PhD (University of Calgary)*
- 16:15 Do Cannabinoids have Treatment Potential for Mental Health Problems?

Mood & anxiety disorders

Gabriella Gobbi, MD, PhD (McGill University)

Substance use disorders

Marco Leyton, PhD (McGill University)

Clinical use of cannabis: lessons learned from neuropathic pain

Mark Ware, MD (McGill University)

17:15 Closing remarks

This program meets the accreditation criteria as defined by the Maintenance of Certification program of the Royal College of Physicians and Surgeons of Canada and has been accredited by the Office of Continuing Professional Development, Faculty of Medicine, McGill University for up to 4.25 Section 1 credits.

Through an agreement between the Royal College of Physicians and Surgeons of Canada and the American Medical Association, physicians may convert Royal College MOC credits to AMA PRA Category 1 Credits™. Information on the process to convert Royal College MOC credit to AMA credit can be found at www.ama-assn.org/go/internationalcme. Each physician should claim only credit commensurate with the extent of their participation in the activity.